FOLD - アミカス・セラピュ―ティクス （Amicus Therapeutics Inc.） アミカス・セラピュ―ティクス

PHILADELPHIA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference, being held virtually, on Wednesday, February 15, 2023 at 10:40 a.m. E.T.

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD ) is an "ideal spec." When asked about QuantumScape Corporation (NYSE: QS ), he said, "I think you should take the money and run." Inmode Ltd (NASDAQ: INMD ) is selling for "incredibly cheap," Cramer said, "Frankly, I don’t get it, and that … Full story available on Benzinga.com

CNBC Television published this video item, entitled "Cramer''s lightning round: Amicus Therapeutics is an ideal spec" - below is their description.

"Mad Money" host Jim Cramer rings the lightning round bell, which means he''s giving his answers to callers'' stock questions at rapid speed.

In the current trading session, Amicus Therapeutics Inc.’s (FOLD) stock is trading at the price of $13.45, a gain of 8.33% over last night’s close. So, the stock is trading at a price that is 2.55% less than its 52-week high of $13.12 and 127.66% better than its 52-week low of $5.91. Based on the […]

PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 9, 2023 at 2:15 p.m. PT.

Investors lose billions as stock hedge funds tank again in 2022 Submitted 29/12/2022 - 11:12am A number of once-high-flying stock hedge funds have racked up a second consecutive year of losses erasing billions of dollars of clients'' wealth in the process, according to a report by Bloomberg. The report cites unnamed sources as revealing that Light Street, Whale Rock Capital Management, Tiger Global Management and Perceptive Advisors have all posted declines of more than 40% over the last two years. And with investors paying lower, or in some cases, no fees on gains until losses are recovered, smaller firms could be heading for problems. After racking up big gains as high-profile tech and healthcare stocks including Meta Platforms, Tesla, and Amicus Therapeutics, soared, this year''s rapid inflation rises saw this same stocks tanked with many funds missing out on the opportunity to up short bets and benefit from their fall. Chase Coleman’s Tiger Global hedge fund has lost 57% over the past two years, which in dollar terms means it has erased all the gains it made since the end of 2018.

CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term Enzyme Replacement Therapy in Combination with Miglustat for both ERT-Experienced and Treatment-Naïve Adults Living with Late-Onset Pompe Disease CHMP Opinion for Miglustat, the Oral Enzyme Stabilizer Component of

CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data

A panel of the European Medicines Agency ((EMA)) recommended the approval of Amicus Therapeutics'' (FOLD) Pombiliti (cipaglucosidase alfa), in combination with the enzyme…

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. New molecular entity approvals drew a blank in August. NMEs are those active moieties that have not been previously approved by the FDA. This should be a cause of concern, as NME approvals are considered a measure of innovation in drug research. The fortunate ones that could take their drugs past the finish line included bluebird bio, Inc. (NASDAQ: BLUE ), Johnson & Johnson (NYSE: JNJ ), and Axsome Therapeutics, Inc. (NASDAQ: AXSM ). ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD ) faced rejection for expanding the label of its Nuplazid to be able to treat Alzheimer’s disease psychosis. CorMedix, Inc.’s (NASDAQ: CRMD ) defencath application was shot down by the FDA for a second time. The review period for Amicus Therapeutics, Inc.’s (NASDAQ: FOLD ) Pompe disease treatment was extended. The Prescription Drug User Fee Act, or PDUFA, date is the period by which the FDA is required to rule on an application submitted by a sponsor company.

In Monday’s session, Amicus Therapeutics Inc. (NASDAQ:FOLD) marked $11.36 per share, up from $11.30 in the previous session. While Amicus Therapeutics Inc. has overperformed by 0.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, FOLD rose by 0.89%, with highs and lows ranging from $12.96 to […]

Amicus Therapeutics Inc. (NASDAQ:FOLD) shares, rose in value on Thursday, 08/25/22, with the stock price down by -4.00% to the previous day’s close as strong demand from buyers drove the stock to $12.24. Actively observing the price movement in the last trading, the stock closed the session at $12.75, falling within a range of $12.0809 … Amicus Therapeutics Inc. (NASDAQ: FOLD): Overvalued In Comparison To Others? Read More »

The trading price of Amicus Therapeutics Inc. (NASDAQ:FOLD) floating lower at last check on Monday, August 22, closing at $11.77, -1.92% lower than its previous close. Traders who pay close attention to intraday price movement should know that it has been fluctuating between $11.77 and $12.12. In examining the 52-week price action we see that … Amicus Therapeutics Inc. (NASDAQ: FOLD) Drops -1.92 Percent In Recent Session, Why Are You Interested? Read More »

Amicus Therapeutics'' AT-GAA approval in Pompe Disease has been pushed back by 3 months. However, the stock seems buoyant enough. Here''s what I''m doing with my position in FOLD stock.